Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201408-03 Development of oral low molecular weight heparin, STP02-3725, as an anticoagulant drug(Cardiovascular Diseases, Chemical) [12.05.2014]

PRINT

Development and Market Objectives

To develop a new orally absorbable anticoagulant by performing efficacy study, process development and manufacture, PK/PD/TK study, and by verifying mechanism of action for preclinical studies.

Unmet Medical Need & Target Patients

Target Patients
1. Deep vein thrombosis & pulmonary thromboembolism
2. Atrial fibriliation
3. Cancer associated thrombosis

Unmet Medical Need
1. Explore orally absorbable anticoagulants to replace the intravenous regimen of heparin
2. High demands for new anticoagulants to replace vitamin K antagonist warfarin showing severe toxicity, drug-drug interactions and slow reaction rate.  
3. Improved antithrombotic effect and safety than FXa inhibitors’ (aka Xaban series).  

Status

• A novel low molecular weight heparin used in the treatment of venous thrombosis and the prevention of thromboembolic events has been developed by adopting bile acid derivatives. 
• Excellent Factor Xa activity
• Good PK properties in rodent
• POC PD assay in DVT rodent model completed
• No toxicity issues observed in 14-day DRF studies (rat & monkey)

Intellectual Property

Strong IP positions of the lead substances and ready for the advanced and process patent filings of the back-up series   

Competitive Advantages

New oral delivery technology of low-molecular weight heparins using tetraDOCA  
Planning high efficacy and de-risk on the bleeding side-effect
Ample network with global pharmaceutical and biotech companies and diverse business development experience

Indication

Thrombosis

Research Period

Dec, 2014 ~ Jun, 2015

Company

ST PHARM, Co., Ltd.

Developmental Stage

Lead Optimization

Additional Information

Contact Information

Contact
Address Company Name: ST PHARM, Co., Ltd.
WebSite Homepage: http://www.stpharm.co.kr/ Contact Person: Dr. Kyungjin Kim
E-mail: kyungjin.kim@stpharm.co.kr Contact: +82-31-488-1402

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code